25 Results for "

ZR-75-1

" in MedChemExpress (MCE) Product Catalog:
Products (25)

25 Results for "ZR-75-1" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-14543
CAS No.: 106516-24-9
Purity:  99.92%
Synonyms: Lu 23-174
Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and αl-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16023A
CAS No.: 182167-02-8
Synonyms: EM-652; SCH 57068
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Acolbifene (EM-652), the active metabolite of EM800, is an orally active pure antiestrogen and selective estrogen receptor antagonist. Acolbifene (EM-652) inhibits estradiol (E2)-induced transcriptional activity of ERα (IC50 = 2 nM) and ERβ (IC50 = 0.4 nM). Acolbifene (EM-652) possesses potent and pure anticarcinogenic properties .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16023
CAS No.: 252555-01-4
Synonyms: EM-652 hydrochloride; SCH 57068 hydrochloride
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Acolbifene (EM-652) hydrochloride, an active metabolite of EM800, is an orally active, cancer-preventing selective estrogen receptor modulator (SERM). Acolbifene (EM-652) hydrochloride inhibits estradiol (E2)-induced transcriptional activity of ERα (IC50=2 nM) and ERβ (IC50=0.4 nM). Acolbifene (EM-652) hydrochloride exerts a potent and pure antiestrogenic action in the mammary gland and uterus. Anticarcinogenic properties .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-133120
CAS No.: 2503017-97-6
Purity:  99.74%
Target:  

PROTACs Akt

Research Areas:  

Cancer

INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-142035
CAS No.: 58160-95-5
Purity:  99.70%
N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-100764
CAS No.: 708991-09-7
Purity:  99.56%
Target:  

Histone Demethylase

Research Areas:  

Cancer

YUKA1 is a potent and cell permeable Lysine demethylase 5A (KDM5A) inhibitor, with an IC50 of 2.66 μM. YUKA1 has less inhibitory active on KDM5C (IC50 = 7.12 μM) and is inactive on KDM5B, KDM6A or KDM6B. YUKA1 can increase H3K4me3 levels and inhibit cell proliferation. YUKA1 can be used for the research of cancer, such as lung and breast cancers .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-133120A
Purity:  99.27%
Target:  

PROTACs Akt

Research Areas:  

Cancer

INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003). INY-03-041 trihydrochloride inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively .
loading...
    loading...
Cat. No.: HY-153444
CAS No.: 2569008-99-5
Purity:  99.62%
Synonyms: PF-07248144
Research Areas:  

Cancer

Prifetrastat (PF-07248144), a first-in-class, selective, and orally active KAT6A and KAT6AB inhibitor. Prifetrastat can be used for the study of ER+/HER2− breast cancer .
loading...
    loading...
Cat. No.: HY-13702
CAS No.: 63612-50-0
Purity:  99.66%
Synonyms: Nilandron; RU 23908
Research Areas:  

Infection Endocrinology Cancer

Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties .
loading...
    loading...
Cat. No.: HY-U00447
CAS No.: 38275-34-2
Research Areas:  

Cancer

PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 proteins by covalent cysteine modification without compromising DNA binding. PK11000 has anti-tumor activities .
loading...
    loading...
Cat. No.: HY-P99591
CAS No.: 372075-37-1
Synonyms: AS1402; huHMFG-1; Epitumomab

Target:  

Mucin

Research Areas:  

Cancer

Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer .
loading...
    loading...
Cat. No.: HY-122182
CAS No.: 2093401-33-1
Purity:  98.64%
Research Areas:  

Cancer

OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .
loading...
    loading...
Cat. No.: HY-122665
CAS No.: 2000209-42-5
Purity:  98.64%
Research Areas:  

Cancer

HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research .
loading...
    loading...
Cat. No.: HY-121435
CAS No.: 1346513-17-4
Purity:  98.24%
Research Areas:  

Cancer

K-8012 is a Sulindac (HY-B0008) analog and RXRα antagonist with an IC50 of 9.2 µM. K-8012 inhibits the activation of AKT. K-8012 induces Apoptosis, redirecting the TNFα signaling pathway from survival to death. K-8012 exerts anticancer activity against lung cancer, prostate cancer, and breast cancer. K-8012 can be used in research related to lung cancer, prostate cancer, breast cancer, and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-123868
CAS No.: 284045-56-3
Target:  

Steroid Sulfatase

Research Areas:  

Cancer

KW-2581 is a steroidal selective steroid sulfatase (STS) inhibitor with an IC50 of 4 nM. KW-2581 inhibits STS activity of ZR-75-1 cells with an IC50 of 13 nM. KW-2581 inhibits the E1S-stimulated growth of ZR-75-1 cells with an IC50 of 0.18 nM. KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells both in vitro and in vivo. KW-2581 induced regression in E1S-induced tumor growth. KW-2581 can be studied in research on hormone receptors-positive breast cancer .
loading...
    loading...
Cat. No.: HY-122665A
Purity:  98.01%
Research Areas:  

Cancer

HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research .
loading...
    loading...
Cat. No.: HY-N2741
CAS No.: 357645-16-0
Vitexin B-1 is an inhibitor of Bcl-2 and the agonist of Caspase. Vitexin B-1 has cytotoxic effect and induces apoptosis in MCF-7, ZR-75-1, MDA-MB-231, and COC1 cells with IC50s of 3.2, 2.1, 1.8 and 0.39 μM, respectively .
loading...
    loading...
Cat. No.: HY-P11255
Target:  

MDM-2/p53

Research Areas:  

Cancer

SPDI-48-T1 is a lysine-stapled peptide. SPDI-48-T1 exhibits discernible binding affinities for MDM2 and MDMX, with Kd values of 396 nM and 456 nM, respectively. SPDI-48-T1 exhibits anticancer activity against breast cancer, colorectal cancer, non-small cell lung cancer, cervical cancer, and malignant melanoma .
loading...
    loading...
Cat. No.: HY-110368
CAS No.: 1883548-83-1
Target:  

CDK

Research Areas:  

Cancer

BS-181 dihydrochloride is a potent and selective CDK7 inhibitor (IC50=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC50 values of 880 nM, 3000 nM and 4200 nM, respectively (fails to block CDK1, 4 and 6). BS-181 dihydrochloride inhibits a panel of cancer cells growth (IC50=11.5 μM-37.3 μM) and induces cell apoptosis. BS-181 dihydrochloride has the potential for the research of cancer therapy .
loading...
    loading...
Cat. No.: HY-121149B
CAS No.: 165813-01-4
Synonyms: (E/Z)-3-Hydroxytamoxifen
Research Areas:  

Cancer

(E/Z)-Droloxifene is a mixture of (E)-droloxifene (a selective estrogen receptor modulator) and (Z)-droloxifene. (E)-Droloxifene binds to the estrogen receptor (ER) with an IC50 value of 24 nM in rabbit uterine homogenates. (E)-Droloxifene increases uterine weight in immature rats, and reduces estradiol-induced increases in uterine weight in juvenile rats. (E)-Droloxifene also inhibits 17β-estradiol-stimulated growth of MCF-7, ZR-75-1, and T47D human breast cancer cells. (Z)-Droloxifene binds weakly to ER and has no estrogenic or antiestrogenic activity .
loading...
    loading...